[en] The plasminogen/plasmin system plays a key role in cancer progression, presumably via mediating extracellular matrix degradation and tumour cell migration. High levels of components of the plasminogen activation system, and paradoxically also its inhibitor, plasminogen activator inhibitor 1 (PAI-1), have been correlated with a poor prognosis for patients with cancers of different types. Recent findings clearly suggest that PAI-1 is essential for capillary sprouting during tumour angiogenesis. Moreover, there is accumulating evidence that both the urokinase receptor and PAI-1 are multifunctional proteins involved not only in extracellular matrix proteolysis but also in cellular adhesion and migration through their binding site for vitronectin. The understanding of whether PAI-1 plays a regulatory role in angiogenesis by tightly controlling proteolytic activity or by influencing cell migration could allow a new anti-angiogenic approach for tumour therapy.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Bajou, Khalid ; Université de Liège - ULiège > Département des sciences de la vie > Biologie et génétique moléculaire
Devy, L.
Masson, Véronique ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique CHR
Albert, V.
Frankenne, Francis
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Language :
French
Title :
Role de l'inhibiteur des activateurs de plasminogene de type 1 dans l'angiogenese tumorale
Alternative titles :
[en] Role of Plasminogen Activator Inhibitor Type 1 in Tumor Angiogenesis
Noel, A., Gilles, C., Bajou, K., Emerging roles for proteinases in cancer (1997) Invasion Metastasis, 17 (5), pp. 221-239
Dano, K., Andreasen, P.A., Grondahl-Hansen, J., Plasminogen activators, tissue degradation, and cancer (1985) Adv Cancer Res, 44, pp. 139-266
Liotta, L.A., Steeg, P.S., Stetler-Stevenson, W.G., Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation (1991) Cell, 64 (2), pp. 327-336
Mignatti, P., Rifkin, D.B., Biology and biochemistry of proteinases in tumor invasion (1993) Physiol Rev, 73 (1), pp. 161-195
Folkman, J., Tumor angiogenesis: A possible control point in tumor growth (1975) Ann Intern Med, 82 (1), pp. 96-100
Noel, A., Bajou, K., Masson, V., Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1 (1999) Fibrinolysis Proteol, 13, pp. 220-225
Andreasen, P.A., Kjoller, L., Christensen, L., Duffy, M.J., The urokinase-type plasminogen activator system in cancer metastasis: A review (1997) Int J Cancer, 72 (1), pp. 1-22
Rifkin, D.B., Mazzieri, R., Munger, J.S., Proteolytic control of growth factor availability (1999) APMIS, 107 (1), pp. 80-85
Carmeliet, P., Collen, D., Development and disease in proteinase-deficient mice: Role of the plasminogen, matrix metalloproteinase and coagulation system (1998) Thromb Res, 91 (6), pp. 255-285
Carmeliet, P., Moons, L., Lijnen, R., Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation (1997) Nat Genet, 17 (4), pp. 439-444
Ichinose, A., Fujikawa, K., Suyama, T., The activation of prourokinase by plasma kallikrein and its inactivation by thrombin (1986) J Biol Chem, 261 (8), pp. 3486-3489
Kobayashi, H., Schmitt, M., Goretzki, L., Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA) (1991) J Biol Chem, 266 (8), pp. 5147-5152
Collen, D., On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture (1980) Thromb Haemost, 43 (2), pp. 77-89
Miles, L.A., Plow, E.F., Binding and activation of plasminogen on the platelet surface (1985) J Biol Chem, 260 (7), pp. 4303-4311
Hajjar, K.A., Harpel, P.C., Jaffe, E.A., Nachman, R.L., Binding of plasminogen to cultured human endothelial cells (1986) J Biol Chem, 261 (25), pp. 11656-11662
Gonzalez-Gronow, M., Edelberg, J.M., Pizzo, S.V., Further characterization of the cellular plasminogen binding site: Evidence that plasminogen 2 and lipoprotein a compete for the same site (1989) Biochemistry, 28 (6), pp. 2374-2377
Duggan, C., Maguire, T., McDermott, E., Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer (1995) Int J Cancer, 61 (5), pp. 597-600
Torzewski, M., Sarbia, M., Verreet, P., Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus (1997) Clin Cancer Res, 3 (12 PART 1), pp. 2263-2268
Shiomi, H., Eguchi, Y., Tani, T., Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma (2000) Am J Pathol, 156 (2), pp. 567-575
Pepper, M.S., Sappino, A.P., Stocklin, R., Upregulation of urokinase receptor expression on migrating endothelial cells (1993) J Cell Biol, 122 (3), pp. 673-684
Okada, S.S., Tomaszewski, J.E., Barnathan, E.S., Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro (1995) Exp Cell Res, 217 (1), pp. 180-187
Morimoto, K., Mishima, H., Nishida, T., Otori, T., Role of urokinase type plasminogen activator (u-PA) in corneal epithelial migration (1993) Thromb Haemost, 69 (4), pp. 387-391
Ossowski, L., Russo-Payne, H., Wilson, E.L., Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse (1991) Cancer Res, 51 (1), pp. 274-281
Yu, H.R., Schultz, R.M., Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes (1990) Cancer Res, 50 (23), pp. 7623-7633
Blasi, F., The urokinase receptor. A cell surface, regulated chemokine (1999) APMIS, 107 (1), pp. 96-101
Chapman, H.A., Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration (1997) Curr Opin Cell Biol, 9 (5), pp. 714-724
Waltz, D.A., Chapman, H.A., Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy (1994) J Biol Chem, 269 (20), pp. 14746-14750
Pannekoek, H., Veerman, H., Lambers, H., Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family (1986) EMBO J, 5 (10), pp. 2539-2544
Strandberg, L., Lawrence, D., Ny, T., The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family (1988) Eur J Biochem, 176 (3), pp. 609-616
Schmitt, M., Wilhelm, O., Janicke, F., Urokinase-type plasminogen activator (uPA) and its receptor (CD87): A new target in tumor invasion and metastasis (1995) J Obstet Gynaecol, 21 (2), pp. 151-165
Aertgeerts, K., De Bondt, H.L., De Ranter, C., Declerck, P.J., A model of the reactive form of plasminogen activator inhibitor-1 (1994) J Struct Biol, 113 (3), pp. 239-245
Limongi, P., Resnati, M., Hernandez-Marrero, L., Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells (1995) FEBS Lett, 369 (2-3), pp. 207-211
Frankenne, F., Noel, A., Bajou, K., Molecular interaction involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy (1999) Emerging Therapeutic Targets, 3, pp. 469-481
Estreicher, A., Muhlhauser, J., Carpentier, J.L., The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes (1990) J Cell Biol, 111 (2), pp. 783-792
Deng, G., Royle, G., Seiffert, D., Loskutoff, D.J., The PAI-1/vitronectin interaction: Two cats in a bag? (1995) Thromb Haemost, 74 (1), pp. 66-70
Hekman, C.M., Loskutoff, D.J., Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants (1985) J Biol Chem, 260 (21), pp. 11581-11587
Loskutoff, D.J., Curriden, S.A., Hu, G., Deng, G., Regulation of cell adhesion by PAI-1 (1999) APMIS, 107 (1), pp. 54-61
Stoop, A., Van Meijer, M., Horrevoets, A.J.G., Pannekoek, H., Molecular advances in plasminogen activator inhibitor 1 interaction with thrombin and tissue-type plasminogen activator (2001) Trends Cardiovasc Med, 7, pp. 47-51
Knudsen, B.S., Harpel, P.C., Nachman, R.L., Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells (1987) J Clin Invest, 80 (4), pp. 1082-1089
Stahl, A., Mueller, B.M., Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system (1997) Int J Cancer, 71 (1), pp. 116-122
Wei, Y., Waltz, D.A., Rao, N., Identification of the urokinase receptor as an adhesion receptor for vitronectin (1994) J Biol Chem, 269 (51), pp. 32380-32388
Deng, G., Curriden, S.A., Wang, S., Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? (1996) J Cell Biol, 134 (6), pp. 1563-1571
Kanse, S.M., Kost, C., Wilhelm, O.G., The urokinase receptor is a major vitronectin-binding protein on endothelial cells (1996) Exp Cell Res, 224 (2), pp. 344-353
Cubellis, M.V., Wun, T.C., Blasi, F., Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1 (1990) EMBO J, 9 (4), pp. 1079-1085
Conese, M., Nykjaer, A., Petersen, C.M., alpha-2 macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor (1995) J Cell Biol, 131 (6 PART 1), pp. 1609-1622
Stefansson, S., Lawrence, D.A., The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin (1996) Nature, 383 (6599), pp. 441-443
Sugiura, Y., Ma, L., Sun, B., The plasminogen-plasminogen activator (PA) system in neuroblastoma: Role of PA inhibitor-1 in metastasis (1999) Cancer Res, 59 (6), pp. 1327-1336
Pyke, C., Kristensen, P., Ralfkiaer, E., The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma (1991) Cancer Res, 51 (15), pp. 4067-4071
Pepper, M.S., Ferrara, N., Orci, L., Montesano, R., Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells (1991) Biochem Biophys Res Commun, 181 (2), pp. 902-906
Stephens, R.W., Brunner, N., Janicke, F., Schmitt, M., The urokinase plasminogen activator system as a target for prognostic studies in breast cancer (1998) Breast Cancer Res Treat, 52 (1-3), pp. 99-111
Pedersen, H., Brunner, N., Francis, D., Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue (1994) Cancer Res, 54 (17), pp. 4671-4675
Donati, M.B., Cancer and thrombosis: From Phlegmasia alba dolens to transgenic mice (1995) Thromb Haemost, 74 (1), pp. 278-281
Eitzman, D.T., Krauss, J.C., Shen, T., Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma (1996) Blood, 87 (11), pp. 4718-4722
Tsuchiya, H., Katsuo, S., Matsuda, E., The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice (1995) Gen Diagn Pathol, 141 (1), pp. 41-48
Bajou, K., Noel, A., Gerard, R.D., Absence of host plasminogen activator inhibitor I prevents cancer invasion and vascularization (1998) Nature Med, 4 (8), pp. 923-928
Nicosia, R.F., Ottinetti, A., Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro (1990) Lab Invest, 63 (1), pp. 115-122
Schnaper, H.W., Barnathan, E.S., Mazar, A., Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways (1995) J Cell Physiol, 165 (1), pp. 107-118
Stack, M.S., Gately, S., Bafetti, L.M., Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation (1999) Biochem J, 340 (PART 1), pp. 77-84
Montesano, R., Pepper, M.S., Mohle-Steinlein, U., Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene (1990) Cell, 62 (3), pp. 435-445
Bajou, K., Masson, V., Gerard, R.D., The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: Implications for anti-angiogenic strategies (2001) J Cell Biol, 152 (4), pp. 777-784
